Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $26
Needham analyst Joseph Stringer maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30 to $26.
SVB Leerink Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $28
SVB Leerink analyst Marc Goodman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $31 to $28.
10 Stocks Moving In Wednesday’s After-Hours Session
Gainers
MercadoLibre (NASDAQ: MELI) shares are trading higher after the company reported Q2 EPS of $1.37, up from $1.11 year over year and better-than-expected Q2 sales results.
ACADIA Pharmaceuticals Q2 EPS $(0.27) Beats $(0.31) Estimate, Sales $115.20M Miss $126.15M Estimate
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.31) by 12.9 percent. This is unchanged from the same period last year. The company
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
Acadia Pharmaceuticals Inc. Highlights Publication Of Results From Phase 3 HARMONY Study In The New England Journal Of Medicine
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced today that the New England Journal of Medicine published results from the Phase 3 HARMONY study, an international, double-blind, placebo-controlled relapse prevention
Alzheimer’s Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What’s Next?
For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.
Understanding ACADIA Pharmaceuticals’s Unusual Options Activity
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $23.25.